Heliprobe System is a “doctor’s office test” for the presence of the gastric ulcer bacterium, Helicobacter pylori. The product has a number of advantages including high reliability, painless administration, a short test time and on-site results.
| Description |
Breath test for diagnosis of Helicobacter pylori |
| Acttive substance |
14C-urea |
| Sales |
Distribution in over 50 countries |
Market
An estimated 260 million people in the world are infected with Helicobacter pylori. The bacteria infects the mucous membrane of the stomach and is a critical factor in the incidence of gastric ulcers. Moreover, Helicobacter pylori has shown to be associated with a multiplied risk of stomach cancer.
Heliprobe is reliable breath test system with a number of unique properties compared with other breath tests. The rapidly dissolving capsule (HeliCap), BreathCard and analysis instruments provide such advantages as high reliability, painless administration, short test time and on-site results.
Marketing and sales
Orexo’s subsidiary Kibion conducts marketing and sales of the Heliprobe System, which was launched in 2001 and is currently sold in more than 50 countries in Europe and the Middle East, Latin America and Asia.